Skip to main content

Bifidobacterium bifidum Shows More Diversified Ways of Relieving Non-Alcoholic Fatty Liver Compared with Bifidobacterium adolescentis

  • 2021-12-31
  • Biomedicines 10(1)
    • Linlin Wang
    • Ting Jiao
    • Q. Yu
    • Jialiang Wang
    • Luyao Wang
    • G. Wang
    • Hao Zhang
    • Jianxin Zhao
    • Wei Chen

Abstract

The occurrence of non-alcoholic fatty liver disease (NAFLD) is closely related to intestinal microbiota disturbance, and probiotics has become a new strategy to assist in alleviating NAFLD. In order to investigate the effect of Bifidobacterium on NAFLD and the possible pathway, a NAFLD model was established by using a high-fat diet (HFD) for 18 weeks. Fourteen strains of Bifidobacterium were selected (seven Bifidobacterium adolescentis and seven Bifidobacterium bifidum) for intervention. The effects of different bifidobacteria on NAFLD were evaluated from liver cell injury, liver fat deposition, liver inflammatory state and liver histopathology, and were taken as entry points to explore the mitigation approaches of bifidobacteria through energy intake, lipid metabolism, glucose metabolism and intestinal permeability. The results showed that Bifidobacterium exerts species-specific effects on NAFLD. B. bifidum exerted these effects mainly through regulating the intestinal microbiota, increasing the relative abundance of Faecalibaculum and Lactobacillus, decreasing the relative abundance of Tyzzerella, Escherichia-Shigella, Intestinimonas, Osillibacter and Ruminiclostridium, and further increasing the contents of propionic acid and butyric acid, regulating lipid metabolism and intestinal permeability, and ultimately inhibiting liver inflammation and fat accumulation to alleviate NAFLD. B. adolescentis exerted its effects mainly through changing the intestinal microbiota, increasing the content of propionic acid, regulating lipid metabolism and ultimately inhibiting liver inflammation to alleviate NAFLD.

Keywords: Bifidobacterium adolescentis; Bifidobacterium bifidum; gut microbiota; non-alcoholic fatty liver disease; short chain fatty acids.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium adolescentisReduced Liver InflammationBeneficial
Large
Bifidobacterium adolescentis iVS-1Reduced InflammationBeneficial
Large
Bifidobacterium bifidumImproved Blood Lipid MetabolismBeneficial
Moderate
Bifidobacterium bifidumImproved Gut PermeabilityBeneficial
Moderate
Bifidobacterium bifidumIncreased Short-Chain Fatty Acid LevelsBeneficial
Moderate
Bifidobacterium bifidumReduced Hepatic Fat AccumulationBeneficial
Large
Bifidobacterium bifidumReduced Liver InflammationBeneficial
Large
Bifidobacterium bifidumRegulated Intestinal MicrobiotaBeneficial
Moderate
Bifidobacterium bifidum HA-132Improved Abundance of Beneficial BacteriaBeneficial
Large
Bifidobacterium bifidum HA-132Reduced InflammationBeneficial
Large
Bifidobacterium bifidum HA-132Reduced Liver Fat AccumulationBeneficial
Large
Bifidobacterium bifidum MAK53B66BImproved Blood Lipid MetabolismBeneficial
Moderate
Bifidobacterium bifidum MAK53B66BImproved Gut PermeabilityBeneficial
Moderate
Bifidobacterium bifidum MAK53B66BRegulated Intestinal MicrobiotaBeneficial
Moderate
Bifidobacterium bifidum VPro 51Alleviated Non-Alcoholic Fatty Liver DiseaseBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.